Lupin, one of the leading pharmaceutical companies in India, witnessed a rise in share price on Thursday after it announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the authorized generic for G.D. Searle LLC's (a subsidiary of Pfizer Inc.) Celebrex Capsules (Celebrex) 50 mg, 100 mg, 200 mg and 400 mg strengths.

Lupin had earlier signed a licensing agreement with Pfizer Inc. regarding Celebrex. Celebrex Capsules had annual U.S sales of USD 2.54 billion (IMS MAT September, 2014).

Shares of the company are trading at Rs 1,444.45, up Rs 13.55, or 0.95% at the Bombay Stock Exchange (BSE) on Thursday at 1:03 p.m.

The scrip has touched an intra-day high of Rs 1,445.80 and low of Rs 1,418.05. The total volume of shares traded at the BSE is 22,254.